INVESTOR ALERT: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MRK

Core Viewpoint - The Merck & Co., Inc. class action lawsuit alleges that the company and its executives made misleading statements regarding the company's revenue outlook and growth prospects for Gardasil, leading to significant stock price declines when the truth was revealed [3][4][5]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Merck created a false impression of reliable information about its revenue outlook and growth of Gardasil while downplaying competition risks and drug approval developments [3]. - It is alleged that Merck's optimistic reports regarding growth and demand in China were not reflective of the actual situation, which showed diminished ability to drive demand for Gardasil [3]. Group 2: Stock Price Impact - Following the announcement on July 30, 2024, regarding a significant drop in shipments from its distributor, Merck's stock price fell nearly 10% [4]. - On February 4, 2025, after disclosing a 3% decline in Gardasil sales to $8.6 billion, Merck's stock price dropped more than 9% [5]. Group 3: Class Action Process - Investors who purchased Merck securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having secured$ 6.6 billion for investors in class action cases [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in six out of the last ten years [7].